Clinical trial
Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation…
NCT02239276 · Cook Children's Health Care System, Other · No longer available
Key facts
| NCT number | NCT02239276 |
|---|---|
| Title | Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies |
| Official title | Expanded Access Use of Stiripentol in Participants With Dravet Syndrome or Epileptic Encephalopathies Associated With Sodium Channel Mutations |
| Lead sponsor | Cook Children's Health Care System, Other |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Dravet Syndrome, Epileptic Encephalopathies Associated With SCN1A Mutations |
| Intervention type | Drug |
| Interventions | Stiripentol |
| First posted | Sep 12, 2014 |
| Last update posted | Feb 5, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: